Reported
Lowest–highest estimate
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Zealand Pharma A/S
OTC:ZLDPF
Zealand Pharma A/S
OTC:ZLDPF
Price:
33.98
USD
1.77%
Market Closed
Market Cap:
$2.4B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Z
|
Zealand Pharma A/S
OTC:ZLDPF
|
DK |
Wall St Price Targets
ZLDPF Price Forecast
Based on 17 analysts
Based on 17 analysts
+88% Upside
from
$33.98
today
Zealand Pharma A/S (ZLDPF)’s 12-month stock price forecast through October 2027 has a consensus target of $64.02, implying 88% upside. The forecast is based on price targets from 17 Wall Street analysts.
ZLDPF Analyst Rating
No ratings yet
No ratings yet
Zealand Pharma A/S Competitors:
Price Targets
Price Targets
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is ZLDPF's stock price target?
Price Target
64.02
USD
64.02
USD
According to Wall Street analysts, the average 1-year price target for ZLDPF is 64.02 USD with a low forecast of 44.75 USD and a high forecast of 116.29 USD.
What is the Revenue forecast for Zealand Pharma A/S?
Projected CAGR
-7%
-7%
Over the last 13 years, the compound annual growth rate for Revenue has been 33%. The projected CAGR for the next 8 years is -7%.
What is the Gross Profit forecast for Zealand Pharma A/S?
Projected CAGR
-64%
-64%
The compound annual growth rate for Gross Profit over the next 3 years is -64%.
What is the Operating Income forecast for Zealand Pharma A/S?
Projected CAGR
-18%
-18%
Over the last 13 years, the compound annual growth rate for Operating Income has been 51%. The projected CAGR for the next 8 years is -18%.